LYNPARZA (Olaparib) - Important Safety Information from AstraZeneca Pharmaceuticals (Ireland) DAC as approved by the HPRA

Notice type: 3rd Party Publications

Date: 27/11/2020




Problem Or Issue:

 

Important Safety Information from AstraZeneca Pharmaceuticals (Ireland) DAC on Risk of medication errors with new pharmaceutical form of LYNPARZA (Olaparib)

 

Important Safety Information - LYNPARZA (Olaparib)


« Back